The ability of iadademstat to efficiently and specifically target the on/off LSD1-driven SOX2 regulatory process that provides higher tumorigenic potential to cells with an epigenetically acquired CSC phenotype [61, 72] might open new therapeutic horizons that incorporate iadademstat in the anti-breast cancer armamentarium. Here, KDM1A is linked to breast carcinoma.